Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aclidinium bromide/formoterol - AstraZeneca

Drug Profile

Aclidinium bromide/formoterol - AstraZeneca

Alternative Names: Aclidinium bromide/formoterol fumarate; BrimicaGenuair; Duaklir Pressair; Duaklir®; DuaklirGenuair; Formoterol fumarate/aclidinium bromide; KRP-AB1102F; LAS40464

Latest Information Update: 24 Apr 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Laboratorios Almirall
  • Developer Allergan; Almirall S.A.; AstraZeneca; Circassia; Forest Laboratories; Kyorin Pharmaceutical
  • Class Antiasthmatics; Antibronchitics; Bronchodilators; Ethanolamines; Quinuclidines; Small molecules; Tropanes
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Cholinergic receptor antagonists; Muscarinic M3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease

Most Recent Events

  • 17 Apr 2019 Adverse events data from the phase III AMPLIFY trial in Chronic obstructive pulmonary disease released by Circassia Pharmaceuticals
  • 01 Apr 2019 Circassia Pharmaceuticals plans to launch aclidinium bromide/formoterol in USA in the second half of 2019
  • 29 Mar 2019 Registered for Chronic obstructive pulmonary disease in USA (Inhalation) (Circassia pipeline, April 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top